National Cancer Society Malaysia (NCSM) and Gene Solutions have announced the signing of a Memorandum of Understanding (MoU) to collaborate on expanding awareness and enabling access to multi-cancer early detection (MCED) testing for the Malaysian population.

This landmark partnership was recently inked at the inaugural National Cancer Congress Malaysia 2024 and aims to revolutionise cancer detection and improve early diagnosis rates across the nation.

The MoU marks a significant step forward in the fight against cancer in Malaysia. By combining NCSM's extensive network and outreach capabilities with Gene Solutions' cutting-edge MCED technology, this collaboration is set to enhance awareness about the importance of early cancer detection and provide accessible testing options to a broader segment of the population.

The collaboration will focus on joint initiatives to educate the public about the benefits and availability of MCED testing, emphasizing the importance of early detection in improving treatment outcomes; Organizing workshops, seminars, and health fairs to reach diverse communities to provide information and resources related to MCED testing; Developing strategies to make MCED tests affordable and accessible, ensuring that more Malaysians can benefit from advanced cancer detection technologies; and Collaborating on projects to gather data on the effectiveness and impact of MCED testing in the Malaysian context, contributing to knowledge and best practices in cancer detection.